NRIX Nurix Therapeutics Inc.

38.71
+1.35  (+4%)
Previous Close 37.36
Open 37.17
52 Week Low 15.21
52 Week High 41.65
Market Cap $1,504,094,044
Shares 38,855,439
Float 25,439,651
Enterprise Value $1,108,275,723
Volume 146,535
Av. Daily Volume 174,727
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
NX-2127
Non-Hodgkin lymphoma /chronic lymphocytic leukemia
Phase 1
Phase 1
Phase 1 trial planned. IND to be filed 4Q 2020 or 1Q 2021.

Latest News

  1. SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences:

    Stifel 2020 Virtual Healthcare Conference, November 16-18, 2020,
    Presenters: Arthur Sands, M.D., Ph.D., CEO and Hans Van Houte, CFO
    Presentation type: Fireside chat
    Presentation date: Tuesday, November 17, 2020 Time: 3:20 p.m. – 3:50 p.m. EST.
    The live presentation can be accessed via a link on the Events and Presentations page of the Nurix Therapeutics website.

    Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020
    Presenter: Arthur Sands, M.D., Ph.D., CEO
    Presentation

    SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences:

    Stifel 2020 Virtual Healthcare Conference, November 16-18, 2020,

    Presenters: Arthur Sands, M.D., Ph.D., CEO and Hans Van Houte, CFO

    Presentation type: Fireside chat

    Presentation date: Tuesday, November 17, 2020 Time: 3:20 p.m. – 3:50 p.m. EST.

    The live presentation can be accessed via a link on the Events and Presentations page of the Nurix Therapeutics website.

    Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020

    Presenter: Arthur Sands, M.D., Ph.D., CEO

    Presentation type: Fireside chat

    A recording of the presentation will be available on the Events and Presentations page of the Nurix Therapeutics website from 10:00 a.m. EST on November 23, 2020.

    The presentations will be archived for 30 days and available on the  Events and Presentations page of the Nurix Therapeutics website.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Contacts:

    Investors:Media:
    Jason Kantor, Ph.D.Elizabeth Wolffe, Ph.D.
    Nurix Therapeutics, Inc.Wheelhouse Life Science Advisors

    Primary Logo

    View Full Article Hide Full Article
  2. SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5th Medicinal Chemistry & Protein Degradation Summit and preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

    Additional details on the presentations:

    5th Medicinal Chemistry & Protein Degradation Summit
    Title: Harnessing DNA-encoded libraries and targeted protein degradation for the discovery of new therapeutics
    Presenter: Dan Robbins, Senior Scientist…

    SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5th Medicinal Chemistry & Protein Degradation Summit and preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

    Additional details on the presentations:

    5th Medicinal Chemistry & Protein Degradation Summit

    Title: Harnessing DNA-encoded libraries and targeted protein degradation for the discovery of new therapeutics

    Presenter: Dan Robbins, Senior Scientist, Medicinal Chemistry

    Date: Monday, November 16, 2020

    Time: 11:05 p.m. EST

    62nd ASH Annual Meeting and Exposition

    Session: Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III

    Title: NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

    Presenter: Dan Robbins, Senior Scientist, Medicinal Chemistry

    Date: Monday, December 7, 2020

    Time: 10:00 a.m. – 6:00 p.m. EST

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Contacts:

    Investors:Media:
    Jason KantorElizabeth Wolffe, Ph.D.
    Nurix Therapeutics, Inc.Wheelhouse Life Science Advisors
     





    Primary Logo

    View Full Article Hide Full Article
  3. SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company's Board of Directors effective November 1, 2020. Dr. Tjian ("Tij") has served as a member of our Board of Directors since November 2016. Dr. Tjian will continue to provide guidance and advice to Nurix in his new role as Chairman of Nurix's Scientific Advisory Board.

    "I have been impressed with the scientific achievements the Nurix team has made in both basic and translational science around E3 ligases, an extremely challenging target class," said Dr. Tjian. "From the early days when I first initiated the discussion around…

    SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company's Board of Directors effective November 1, 2020. Dr. Tjian ("Tij") has served as a member of our Board of Directors since November 2016. Dr. Tjian will continue to provide guidance and advice to Nurix in his new role as Chairman of Nurix's Scientific Advisory Board.

    "I have been impressed with the scientific achievements the Nurix team has made in both basic and translational science around E3 ligases, an extremely challenging target class," said Dr. Tjian. "From the early days when I first initiated the discussion around the formation of Nurix with my colleagues Micha Rape and John Kuriyan at the University of California, Berkeley and Art Weiss at the University of California, San Francisco, to our now much anticipated initiation of clinical trials for our first drug candidates, Nurix has been and will continue advancing on an exciting scientific and medical journey to bring potential breakthrough therapies to patients with cancer deploying powerful new disease modifying modalities."

    "On behalf of the entire Nurix team, I would like to thank Tij for his service over the past four years and his continued commitment to Nurix in his new role as Chairman of our Scientific Advisory Board," said Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix. "Tij will continue to be the scientific North Star for Nurix as we explore the E3 ligase drug discovery space to bring targeted protein modulation drugs into clinical trials."

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Forward Looking Statement

    Any statements made in this press release relating to future business performance, conditions, plans, prospects, trends, or strategies and other business matters, including statements regarding our plans with respect to finding a highly qualified independent board member for Nurix's board of directors and our ability to advance multiple wholly owned drugs into clinical development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions regarding the future of the Company's business, future plans and strategies, its development plans, its preclinical results and other future conditions. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from those expressed or implied in our forward-looking statements due to a variety of factors, including the risks and uncertainties described under the heading "Risk Factors" in our final prospectus pursuant to Rule 424(b)(4) filed with the Securities and Exchange Commission (SEC) on July 24, 2020, our Quarterly Report on Form 10-Q filed with the SEC on October 14, 2020 and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

    Contacts:



    Investors:

    Jason Kantor

    Nurix Therapeutics, Inc.





    Media:

    Cherilyn Cecchini, M.D.

    LifeSci Communications



    Primary Logo

    View Full Article Hide Full Article
  4. Completed recent IPO raising approximately $238.5 million in gross proceeds

    On track for multiple IND filings

    SAN FRANCISCO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics Inc. (NASDAQ:NRIX), a biotechnology company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2020 and provided a corporate update.

    Recent Business Highlights

    • Strengthened Leadership Team with Key Appointments. Added Dr. Michael Lotze as chief cellular therapy officer and Dr. Robert Brown as vice president of clinical development to help advance protein modulating drug candidates and cell therapy programs into the clinic. Also enhanced the financial team with the…

    Completed recent IPO raising approximately $238.5 million in gross proceeds

    On track for multiple IND filings

    SAN FRANCISCO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics Inc. (NASDAQ:NRIX), a biotechnology company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2020 and provided a corporate update.

    Recent Business Highlights

    • Strengthened Leadership Team with Key Appointments. Added Dr. Michael Lotze as chief cellular therapy officer and Dr. Robert Brown as vice president of clinical development to help advance protein modulating drug candidates and cell therapy programs into the clinic. Also enhanced the financial team with the addition of Dr. Jason Kantor as senior vice president, finance and investment strategy.

    • Completed an Initial Public Offering (IPO) in July 2020 raising approximately $238.5 million in gross proceedsOn July 23, 2020, Nurix announced the pricing of its IPO of 11,000,000 shares of common stock, at a public offering price of $19.00 per share. In addition, the underwriters subsequently exercised their option to purchase 1,550,000 additional shares of common stock. The net proceeds to Nurix from the offering were approximately $218.1 million, after deducting underwriting discounts, commissions and offering expenses.

    • Business Continuity: Nurix is executing upon its business objectives for 2020 and beyond and is on track to complete and file several investigational new drug applications (INDs), even accounting for the impact of the COVID-19 pandemic. Nurix continues to monitor the impact of the pandemic on its operations and the operations of its suppliers, vendors and business partners.

    "Following our successful initial public offering and with our strategic collaborations, we believe we have the resources needed to steadily advance a broad and deep portfolio of protein modulation drug candidates," said Dr. Arthur Sands, president and chief executive officer of Nurix. "The recent additions of Dr. Robert Brown and Dr. Michael Lotze position us well to enter the clinic next year with multiple investigational drug candidates in oncology."

    Upcoming Program Highlights

    • NX-2127: The Company's lead drug candidate from its protein degradation portfolio, NX-2127, is an orally available degrader of Bruton's tyrosine kinase (BTK) with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies. The Company expects to file an IND for NX-2127 with the U.S. Food and Drug Administration (FDA) in late fourth quarter of 2020 or the first quarter of 2021 (expected timing of IND submissions here and throughout the press release are based on calendar year quarters).



    • NX-1607: The Company's lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) for immuno-oncology indications. The Company expects to file an IND for NX-1607 with the FDA in the third quarter of 2021.



    • NX-5948: The Company's second drug candidate from its protein degradation portfolio, NX-5948, is an orally available BTK degrader designed without IMiD activity for certain B-cell malignancies, autoimmune diseases and related diseases such as graft-versus-host disease. The Company anticipates filing an IND with the FDA in the second half of 2021.



    • DeTIL-0255: The Company's lead candidate in its cellular therapy portfolio, DeTIL-0255, is a drug-enhanced adoptive cellular therapy. The Company anticipates filing an IND with the FDA in the second half of 2021.

    Fiscal Third Quarter 2020 Financial Highlights

    Collaboration revenue for the three months ended August 31, 2020 was $4.1 million compared to $10.6 million for the three months ended August 31, 2019. The decrease in collaboration revenue was attributable to the termination of a collaboration agreement with Celgene Corporation in June 2019, which resulted in no revenue recognition in 2020, offset by revenue recognized related to the Company's collaboration agreements with Gilead Sciences, Inc. and Sanofi S.A.

    Research and development expenses for the three months ended August 31, 2020 were $18.9 million compared to $11.0 million for the three months ended August 31, 2019. The increase was primarily related to increases in preclinical development activities and drug discovery research as well as increases in headcount and higher stock-based compensation expense.

    General and administrative expenses for the three months ended August 31, 2020 were $4.3 million compared to $2.2 million for the three months ended August 31, 2019. The increase was primarily related to higher headcount and increased legal and accounting expenses associated with becoming a public company.

    Net loss attributed to common stockholders for the three months ended August 31, 2020 was $18.5 million, or ($0.59) per share, compared to a net loss of $2.4 million, or ($0.66) per share, for the three months ended August 31, 2019.

    Cash, Cash Equivalents and Investments: As of August 31, 2020, the Company had cash, cash equivalents and investments of $395.1 million compared to $38.2 million as of November 30, 2019.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Forward Looking Statement

    Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates; the timing of our planned IND submissions for our product candidates; the planned timing and conduct of our clinical trial programs for our product candidates, preclinical activities, research and development costs, current and prospective collaborations; the potential advantages of our DELigase™ platform and product candidates; the extent to which our scientific approach and DELigase™ platform may potentially address a broad range of diseases; the estimated size of the market for our product candidates; and the timing and success of our development and commercialization of our anticipated product candidates are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions regarding the future of the Company's business, future plans and strategies, its development plans, its preclinical results and other future conditions. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from those expressed or implied in our forward-looking statements due to a variety of factors, including risks and uncertainties related to our ability to advance our product candidates, obtain regulatory approval of and ultimately commercialize our product candidates, the timing and results of preclinical and clinical trials, our ability to fund development activities and achieve development goals, the impact of the COVID-19 pandemic on our business, our ability to protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in our final prospectus pursuant to Rule 424(b)(4) filed with the Securities and Exchange Commission (SEC) on July 24, 2020 and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

    Contacts:



    Investors:

    Jason Kantor

    Nurix Therapeutics, Inc.





    Media:

    Cherilyn Cecchini, M.D.

    LifeSci Communications





    Nurix Therapeutics, Inc.

    Condensed consolidated statements of operations

    (in thousands, except share and per share amounts)

    (unaudited)

     Three Months Ended
     August 31,
      2020   2019 
    Collaboration revenue$4,085  $10,580 
    Operating expenses:   
    Research and development 18,939   11,008 
    General and administrative 4,338   2,184 
    Total operating expenses 23,277   13,192 
    Loss from operations (19,192)  (2,612)
    Interest and other income, net 675   195 
    Loss before provision (benefit) for income taxes (18,517)  (2,417)
    Provision (benefit) for income taxes    10 
    Net loss$(18,517) $(2,427)
    Net loss per share attributable to common stockholders, basic and diluted$(0.59) $(0.66)
    Weighted-average number of shares outstanding, basic and diluted 31,383,936   3,667,335 



    Nurix Therapeutics, Inc.

    Condensed consolidated balance sheets

    (in thousands)

    (unaudited)

     August 31, November 30,
      2020   2019 
    Assets   
    Current assets:   
    Cash and cash equivalents$265,527  $34,816 
    Short-term investments 88,716   2,904 
    Income tax receivable 3,856    
    Prepaid expenses and other current assets 5,990   1,634 
       Total current assets 364,089   39,354 
    Long-term investments 40,898   506 
    Property and equipment, net 6,532   3,871 
    Restricted cash 170   170 
    Other assets 185   147 
       Total assets$411,874  $44,048 
    Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)   
    Current liabilities:   
    Accounts payable$3,611  $1,598 
    Accrued and other current liabilities 7,102   4,927 
    Deferred revenue, current 30,299   9,612 
       Total current liabilities 41,012   16,137 
    Deferred revenue, net of current portion 62,374   35,693 
    Other long-term liabilities 868   1,737 
       Total liabilities 104,254   53,567 
    Redeemable convertible preferred stock    48,195 
    Common stock 39   4 
    Additional paid-in-capital 391,227   2,740 
    Accumulated other comprehensive income (loss) 138   (2)
    Accumulated deficit (83,784)  (60,456)
       Total stockholders' equity (deficit) 307,620   (57,714)
       Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$411,874  $44,048 

    Primary Logo

    View Full Article Hide Full Article
  5. SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ:NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.

    Additional details on the presentation are below:

    3rdTargeted Protein Degradation (TPD) Summit
    Session: Robust Translation Towards Clinical Development
    Title: Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels
    Presenter: Arthur Sands, M.D., Ph.D., CEO
    Date: Wednesday, October 14, 2020
    Time: 1:50 p.m. EDT

    Copies of the slide presentation will be archived and available in the Investors section of the Company's website at www.nurix.com

    SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ:NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.

    Additional details on the presentation are below:

    3rd Targeted Protein Degradation (TPD) Summit

    Session: Robust Translation Towards Clinical Development

    Title: Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels

    Presenter: Arthur Sands, M.D., Ph.D., CEO

    Date: Wednesday, October 14, 2020

    Time: 1:50 p.m. EDT

    Copies of the slide presentation will be archived and available in the Investors section of the Company's website at www.nurix.com.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

    Contacts:

    Investors:

    Jason Kantor

    Nurix Therapeutics, Inc.

    Media:

    Cherilyn Cecchini, M.D.

    LifeSci Communications

    Primary Logo

    View Full Article Hide Full Article
View All Nurix Therapeutics Inc. News